Nature Medicine Publishes Addendum on GFR Slope as Kidney Failure Surrogate Endpoint

An addendum correcting the record on a major kidney-disease analysis was published on Monday, November 16, in Nature Medicine. The addendum, indexed on PubMed the same day, revisits a meta-analysis led by Lesley A. Inker of Tufts Medical Center that examined whether the rate of kidney function decline — the GFR slope — can stand in for kidney failure as a trial endpoint.

The original analysis came from the CKD-EPI Clinical Trials Consortium, a collaboration spanning more than 20 institutions across the United States, Europe, Australia, and Asia. Nature Medicine, the journal carrying the work, listed 86 authors on the addendum, from Tufts Medical Center in Boston to the George Institute for Global Health in Sydney and the University of Oxford in the United Kingdom.

Why does a correction to a statistical paper matter to patients? Because the GFR slope is the measuring stick regulators and drug developers use to decide whether new kidney medicines work — often years before anyone reaches dialysis. If that measuring stick is miscalibrated, approvals slow down or speed up, and patients wait.

GFR slope tracks kidney decline

  • GFR slope tracks how fast your kidneys lose their filtering ability over time; a steeper downhill slope means faster decline.

What a surrogate endpoint actually does

In a clinical trial — one where neither patients nor investigators know who receives the drug — waiting for enough participants to progress to kidney failure can take a decade. A surrogate endpoint is a substitute measure, here the change in glomerular filtration rate (GFR), the milliliters per minute the kidneys filter, measured over roughly one to two years.

The mechanism of action is straightforward in principle: therapies that protect the kidney’s filtering units, the glomeruli, slow the GFR slope. If a flatter slope reliably predicts fewer people reaching end-stage kidney disease — permanent dialysis or transplant — then trials can be shorter, smaller, and cheaper.

The consortium’s meta-analysis pooled individual patient data from dozens of trials to test exactly that reliability. The addendum, per the PubMed record, formally amends that published analysis; the underlying study page at Nature Medicine carries the same DOI-linked record.

Authorship of kidney trials

The authorship map tells the story of how kidney trials are run today. Lead author Lesley A. Inker and analysts Shiyuan Miao and Juhi Chaudhari sit at Tufts Medical Center’s Division of Nephrology, with statisticians Willem Collier, Tom Greene, and Benjamin Haaland at the University of Utah School of Medicine.

Columbia University Medical Center contributed Gerald B. Appel and Pietro Canetta. The George Institute for Global Health in Sydney and Imperial College London supplied Sunil V. Badve, Brendon L. Neuen, Mark Woodward, John Chalmers, Bruce Neal, Vlado Perkovic, David Johnson, and Meg Jardine — the group behind several of the largest recent kidney-outcome trials.

European centers round out the collaboration: Hospital 12 de Octubre in Madrid, Sant’Anna Hospital in Como, RWTH Aachen University, Gregorio Marañón Hospital in Madrid, the Nuffield Department of Population Health at Oxford, Mario Negri IRCCS in Bergamo, the University of Würzburg, Radboud University Medical Center in Nijmegen, and University Medical Center Groningen, among others.

Asian sites include the Prince of Wales Hospital in Hong Kong, Nakayamadera Imai Clinic in Takarazuka, and Duke-NUS Medical School in Singapore.

Industry names appear in the author list too — reflecting that much of the underlying trial data comes from industry-sponsored studies of kidney and diabetes drugs.

The addendum’s place in the regulatory picture

In the United States, the Food and Drug Administration has long accepted GFR-based measures in chronic kidney disease trials; in Europe, the European Medicines Agency applies comparable expectations. A validated surrogate endpoint shortens that pathway for every market.

Addenda in Nature Medicine are the journal’s formal mechanism for correcting or supplementing a published paper without retracting it. The addendum, dated November 16, 2026, and carrying DOI 10.1038/s41591-026-04798-5, joins the original analysis in the permanent record; readers citing the work are directed to the addendum alongside it.

Item Detail
Article type Addendum to a meta-analysis
Journal Nature Medicine
Publication date November 16, 2026
DOI 10.1038/s41591-026-04798-5
Lead author Lesley A. Inker, Tufts Medical Center, Boston
Collaboration CKD-EPI Clinical Trials Consortium (86 named authors)

What remains open

Those specifics live behind the journal's own pages.

What the sources do establish is the scale of the evidence base behind the original work: a consortium whose investigators ran or analyzed trials across four continents, from the Comprehensive Heart Failure Center in Würzburg. That breadth is what gives a GFR-slope validation its regulatory weight.

When to consult a doctor

Patients with chronic kidney disease should continue routine monitoring of their eGFR and urine albumin through their nephrologist or primary care physician. Any change in kidney function on a lab report warrants a conversation with the clinician managing the underlying condition — diabetes, hypertension, or glomerular disease — before anything else.

Surrogate endpoints in drug approval

Surrogate endpoints are the quiet machinery of modern drug approval.

References

  • Inker LA, Collier W, Greene T, et al. “Addendum: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.” Nature Medicine, published November 16, 2026. DOI: 10.1038/s41591-026-04798-5 — doi.org/10.1038/s41591-026-04798-5
  • PubMed record for the addendum, National Library of Medicine — pubmed.ncbi.nlm.nih.gov/43040107
  • CKD-EPI Clinical Trials Consortium collaborator listing, as published with the article in Nature Medicine.

Consult a qualified healthcare professional regarding any kidney health concerns.

Photo of author

Health Desk

Health Desk at Archyde.

Philippe Promises to Keep Unemployment Scheme for Performers